{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:18Z","timestamp":1793907318507,"version":"4.8.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.2217\/fon.14.51","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T12:49:36Z","timestamp":1403182176000},"page":"957-967","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":185,"title":["Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase"],"prefix":"10.1080","volume":"10","author":[{"given":"Matthew S","family":"Davids","sequence":"first","affiliation":[{"name":"Chronic Lymphocytic Leukemia Center,Dana-Farber Cancer Institute,Department of Medical Oncology,\r          Boston,\r          MA,\r          USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R","family":"Brown","sequence":"additional","affiliation":[{"name":"Chronic Lymphocytic Leukemia Center,Dana-Farber Cancer Institute,Department of Medical Oncology,\r          Boston,\r          MA,\r          USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,6,19]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.1.161"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"e_1_3_2_9_1","first-page":"7","volume-title":"The 55th ASH\u00ae Annual Meeting and Exposition.","author":"Eichhorst B","year":"2013","unstructured":"Eichhorst B , FinkAM , BuschRBet al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of The German CLL Study Group (GCLLSG) . Presented at:The 55th ASH\u00ae Annual Meeting and Exposition.LA, USA , 7 \u2013 10December 2013 ."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_2_11_1","first-page":"7","volume-title":"The 55th ASH\u00ae Annual Meeting and Exposition.","author":"Goede V","year":"2013","unstructured":"Goede V , FischerK , BuschRet al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 2 results of the CLL11 trial . Presented at:The 55th ASH\u00ae Annual Meeting and Exposition.LA, USA , 7 \u2013 10December 2013 ."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_3_2_18_1","first-page":"7","volume-title":"The 55 ASH\u00ae Annual Meeting and Exopsition.","author":"Wilson WH","year":"2013","unstructured":"Wilson WH , GerecitanoJF , GoyAet al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-Cell lymphoma (DLBCL): interim results of a multicenter, open-label, Phase 2 study . Presented at:The 55 ASH\u00ae Annual Meeting and Exopsition.LA, USA , 7 \u2013 10December 2013 ( Abstract 686 )."},{"key":"e_1_3_2_19_1","first-page":"7","volume-title":"The 55 ASH\u00ae Annual Meeting and Exopsition.","author":"Treon SP","year":"2013","unstructured":"Treon SP , TripsasCK , Yang , Get al. A prospective multicenter study of the bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory waldenstrom's macroglobulinemia . Presented at:The 55 ASH\u00ae Annual Meeting and Exopsition.LA, USA , 7 \u2013 10December 2013 ( Abstract 251 )."},{"key":"e_1_3_2_20_1","first-page":"8","volume-title":"The 55 ASH\u00ae Annual Meeting and Exopsition.","author":"Fowler NH","year":"2012","unstructured":"Fowler NH , AdvaniRH , SharmanJPet al. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma . Presented at:The 55 ASH\u00ae Annual Meeting and Exopsition.GA, USA , 8 \u2013 112012 ( Abstract 156 )."},{"issue":"13","key":"e_1_3_2_21_1","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd JC","year":"2013","unstructured":"Byrd JC , O'BrienS , JamesDF . Ibrutinib in relapsed chronic lymphocytic leukemia . N. Engl. J. Med.369 ( 13 ), 1278 \u2013 1279 ( 2013 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.09.008"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511154"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3748"},{"key":"e_1_3_2_26_1","volume-title":"ASCO Annual Meeting.","author":"Chang B","year":"2013","unstructured":"Chang B , FurmanRR , ZapatkaMet al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) . Presented at:ASCO Annual Meeting.IL, USA , 31 May\u20134 June 2013 ( Abstract 7014 )."},{"key":"e_1_3_2_27_1","first-page":"7","volume-title":"The 55th ASH\u00ae Annual Meeting and Exposition.","author":"Burger JA","year":"2013","unstructured":"Burger JA , LandauD , HoellenriegelJet al. Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition . Presented at:The 55th ASH\u00ae Annual Meeting and Exposition.LA, USA7 \u2013 10December 2013 ( Abstract 866"},{"key":"e_1_3_2_28_1","first-page":"7","volume-title":"The 55th ASH\u00ae Annual Meeting and Exposition.","author":"Burger JA","year":"2013","unstructured":"Burger JA , KeatingMJ , WierdaWGet al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a Phase II trial in 40 patients . Presented at:The 55th ASH\u00ae Annual Meeting and Exposition.LA, USA7 \u2013 10December 2013 ( Abstract 675"},{"key":"e_1_3_2_29_1","first-page":"1","volume-title":"2012 ASCO Annual Meeting.","author":"Jaglowski SM","year":"2012","unstructured":"Jaglowski SM , JonesJA , FlynnJMet al. A Phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases . Presented at:2012 ASCO Annual Meeting.IL, USA , 1 \u2013 5June 2012 ( Abstract 6508 )."},{"key":"e_1_3_2_30_1","first-page":"7","volume-title":"The 55 ASH\u00ae Annual Meeting and Exopsition.","author":"Kohrt H","year":"2013","unstructured":"Kohrt H , Sagiv-BarfiI , RafiqSet al. Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity . Presented at:The 55 ASH\u00ae Annual Meeting and Exopsition.LA, USA , 7 \u2013 10December 2013 ( Abstract 373 )."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_3_2_32_1","first-page":"7","volume-title":"The 55 ASH\u00ae Annual Meeting and Exopsition.","author":"Brown JR","year":"2013","unstructured":"Brown JR , BarrientosJC , BarrPMet al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL\/SLL . Presented at:The 55 ASH\u00ae Annual Meeting and Exopsition.LA, USA , 7 \u2013 10December 2013 ( Abstract 525)."},{"key":"e_1_3_2_33_1","unstructured":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma . www.clinicaltrials.gov\/ct2\/show\/NCT01776840"},{"key":"e_1_3_2_34_1","first-page":"7","volume-title":"The 55 ASH\u00ae Annual Meeting and Exopsition.","author":"Younes A","year":"2013","unstructured":"Younes A , FlinnI , BerdejaJet al. Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a Phase 1b study in treatment-naive patients with CD20-positive B-Cell non-Hodgkin's lymphoma (NHL) . Presented at:The 55 ASH\u00ae Annual Meeting and Exopsition.LA, USA , 7 \u2013 10December 2013 ( Abstract 852 )."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-011817"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:43Z","timestamp":1719125023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.2217\/fon.14.51"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.51","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}